APA (7th ed.) Citation

P, P., J, S., T, T., J, P., SJ, K., P, H., . . . R, R. (2023). Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines - A prospective multi-center study. Heliyon, 10(1), e23246. https://doi.org/10.1016/j.heliyon.2023.e23246

Chicago Style (17th ed.) Citation

P, Phuensan, et al. "Immunogenicity and Safety of Heterologous Versus Homologous Prime-boost Schedules with Inactivated and Adenoviral Vectored SARS-CoV-2 Vaccines - A Prospective Multi-center Study." Heliyon 10, no. 1 (2023): e23246. https://doi.org/10.1016/j.heliyon.2023.e23246.

MLA (9th ed.) Citation

P, Phuensan, et al. "Immunogenicity and Safety of Heterologous Versus Homologous Prime-boost Schedules with Inactivated and Adenoviral Vectored SARS-CoV-2 Vaccines - A Prospective Multi-center Study." Heliyon, vol. 10, no. 1, 2023, p. e23246, https://doi.org/10.1016/j.heliyon.2023.e23246.